Wang Liyuan, Xiong Yunyun
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China,
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Eur Neurol. 2023;86(2):95-106. doi: 10.1159/000528922. Epub 2023 Feb 8.
Futile reperfusion (FR) is becoming an urgent issue for acute ischemic stroke patients who underwent endovascular treatment (EVT). Although the recanalization rate has improved after EVT, it is far from translating to increased tissue reperfusion and functional independence.
Many underlying mechanisms including the "no-reflow" phenomenon, poor collateral flow, venous dysfunction, and inflammation were proposed, but the pathophysiology of FR is still unclear. Clinically, reliable predictors are still yet to be identified, and ongoing trials on shortening the time delay and cytoprotection may provide novel ideas for interventions of FR.
This review will summarize the latest advances in FR and hopefully shed light on potential interventions.
对于接受血管内治疗（EVT）的急性缺血性卒中患者而言，无效再灌注（FR）正成为一个紧迫问题。尽管血管内治疗后再通率有所提高，但这远未转化为组织再灌注增加和功能独立性改善。
人们提出了许多潜在机制，包括“无复流”现象、侧支循环不良、静脉功能障碍和炎症，但FR的病理生理学仍不清楚。在临床上，仍有待确定可靠的预测指标，而正在进行的关于缩短时间延迟和细胞保护的试验可能为FR的干预提供新的思路。
本综述将总结FR的最新进展，并有望为潜在干预措施提供启示。
